

# Xenograft and Syngeneic Tumor Models in Rats



WuXi AppTec, WuXi Biology, Oncology & Immunology Unit



2023.03

OncowuXi Newsletter

## Introduction of rat models

### ■ Advantages of Rats in preclinical efficacy studies compared with mice:

- More similar metabolism and physiology to human
- Easier for orthotopic model surgery, vascular manipulation and some types of imaging
- Larger sample size to ensure sufficient amount for analysis
- Consistent animal species to those in toxicology and some DMPK studies

### ■ Widely-used immuno-deficient rats and their severity levels of immuno-deficiency:

Strain	Hair Coat	T-Cell Deficient	B-Cell Deficient	NK-Cell Deficient	Genetics
Nude Rat	No	Yes	No	No	Inbred
FRG Rat	Yes	Yes	Yes	Yes	Inbred
SRG Rat	Yes	Yes	Yes	Yes	Inbred

# Xenograft models in rats

Human cell-line derived xenograft models in rats


- Flexibility with the routes of cell inoculation: subcutaneous, orthotopic or metastatic/systemic models;
- Growth kinetics in different rat strains;
- SOC validation

	Cancer Type	Cell Line
Xenograft Models	Bladder Cancer	RT-112
	Colon Cancer	HCT-116 <sup>s</sup> , HT-29 <sup>s</sup> , DLD-1
	Epidermoid Cancer	A431
	Lymphoma Cancer	SU-DHL-4, Raji <sup>s</sup>
	Myeloma Cancer	MM1S, MM1R
	Leukemia Cancer	THP-1, MV4-11, K562, K562-luc(systemic), MOLM-13, Molt-4-luc (systemic)
	Lung Cancer	NCI-H460 <sup>s</sup> , NCI-H1299, NCI-H1975, A549, NCI-H1373, NCI-H2122, NCI-H441, Calu-6 <sup>s</sup>
	Melanoma Cancer	A375 <sup>s</sup> , A2058
	Ovarian Cancer	A2780 <sup>s</sup> , OVCAR-3
	Prostate Cancer	PC3, 22Rv.1, LNCap
	Pancreatic Cancer	CAPAN-1, Mia-Pa-ca-2, HPAC
	Breast Cancer	MDA-MB-231-luc(SubQ), MDA-MB-231-luc (Orthotopic) <sup>s</sup> , HCC1954 <sup>s</sup> , MCF-7
	Liver Cancer	Hep3B-luc (orthotopic), HepG2
	Glioma	U87-luc2 (Orthotopic)
	Renal Cancer	Caki-1, 786-O


<sup>s</sup>: SOC validated

## Growth curve and SOC data of NCI-H460 in different strains


NCI-H460 in nude rat




NCI-H460 in FRG rat



NCI-H460 in SRG rat



Cisplatin in NCI-H460 model



# Syngeneic models in rats


Rat cell-line derived syngeneic models in rats

- Syngeneic rat models have intact immune systems, enabling the innovation of immunotherapies.
- Immune profiling and additional end-points: Flow-cytometry, multiplex IHC/IF, NGS – Nanostring and scRNAseq.


	Cancer Type	Cell Line
Syngeneic Models	Glioma	C6-luc (SubQ), C6-luc (Orthotopic), F98npEGFRvIII 9L/lacZ
	Hepatoma	N1-S1-luc (Orthotopic)
	Mammary carcinoma	13762 MATBIII
	Sarcoma	XC
	Squamous cell carcinoma	SCC131

## Syngeneic models in immunocompetent rat



C6 in Wistar rats



9L/LacZ in F344 rats



C6-luc orthotopic model in Wistar rats



# Instruments for complex surgeries and drug delivery

Surgical techniques enabling better clinical relevance


## ■ Intravenous drip

Drugs can be delivered into the blood circulation directly, and the injection rate is controllable and adjustable.



## ■ Transcatheter Arterial ChemoEmbolization (TACE)

The commonly used form of locoregional therapy in unresectable HCC.





# OUR COMMITMENT

## *Improving Health. Making a Difference.*

For questions and requests, please email to [info\\_onco@wuxiapptec.com](mailto:info_onco@wuxiapptec.com)



<https://onco.wuxiapptec.com>